Antibodies News and Research

RSS

Pangolin version of SARS-CoV-2 can cause COVID-19-like illness

The results of a recent multinational research endeavor, currently available on the bioRxiv preprint server, display the biological framework of SARS-CoV-2-related coronavirus in pangolins and reveal striking similarities to coronavirus disease (COVID-19) in humans, but also show that it can be transmitted vertically to the fetus.

23 Jun 2020

First clinical trial in South Africa for Covid-19 vaccine begins

The first clinical trial in South Africa and on the continent for a Covid-19 vaccine was announced today, 23 June 2020, at a virtual press conference hosted by the University of the Witwatersrand, Johannesburg (Wits).

23 Jun 2020

White Paper: Separation and characterization of viruses and antibodies

Postnova Analytics have published an informative new white paper that details how multi-detector Asymmetrical Field Flow Fractionation (AF4) and Electrical AF4 (EAF4) techniques are transforming the separation and characterization of viruses and antibodies.

From Postnova Analytics 23 Jun 2020

SARS-CoV-2 induces broad T cell response in recovering patients

A new study published on the preprint server bioRxiv in June 2020 shows that T cell responses in COVID-19 patients are broader and more robust in severe disease and are explicitly directed against spike, memory, and ORF3a proteins.

23 Jun 2020

8.5 percent of COVID-19 patients do not seroconvert

A new study published on the preprint server medRxiv in June 2020 reports on the use of inexpensive and accurate ELISA and rapid diagnostic tests (RDT) to identify the demographic and clinical factors that affect the antibody response in COVID-19 patients.

23 Jun 2020

Scientists find COVID-19 antibodies fade quickly

Now, a new study shows that the levels of antibodies found in recovered coronavirus disease (COVID-19) patients declined sharply in just two to three months after infection for both symptomatic and asymptomatic patients.

23 Jun 2020

Single-dose Israeli vaccine candidate protective against SARS-CoV-2

Now, a new Israeli study published on the preprint server bioRxiv in June 2020 reports a new recombinant vaccine expressing the S or spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to be highly protective with a single dose in an animal model. This could be a gamechanger in the fight to contain the outbreak.

23 Jun 2020

Characterizing SARS-CoV-2 convalescent plasma

A new study published on the preprint server bioRxiv in June 2020 uses serologic correlates to assess the efficacy of convalescent plasma. This will also help to classify donor plasma as more or less potent at neutralizing the virus.

23 Jun 2020

Growth, adaptation and neutralization of SARS-CoV-2 with acute-phase serum

One recent study published on the preprint server bioRxiv in June 2020 reports the results of growing and characterizing the virus, as well as the development of neutralizing antibodies in the serum of acutely infected hospitalized patients with COVID-19.

22 Jun 2020

Prior infection provides protection against SARS-CoV-2 virus in hamsters

In an animal model for COVID-19 that shares important features of human disease, scientists at the University of Wisconsin–Madison, the University of Tokyo and the Icahn School of Medicine at Mount Sinai show that prior infection with the SARS-CoV-2 virus provides protection against reinfection, and treatment with convalescent serum limits virus replication in their lungs.

22 Jun 2020

New insights on antibody testing and RNA testing for SARS-CoV-2

Two types of tests are used to track SARS-CoV-2. Reverse transcriptase PCR (rt-PCR) tests for current infection. Antibody tests reveal that an infection has taken place, even long after the fact.

22 Jun 2020

Three vaccine candidates race to combat SARS-CoV-2

As the coronavirus disease (COVID-19) ravages across the globe, scientists are racing to develop an effective vaccine to combat the viral infection. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the disease has infected nearly 9 million people.

22 Jun 2020

Novel vaccine platform against COVID-19 based on engineered human mesenchymal stem cells

In a recent groundbreaking bioRxiv paper, Chinese researchers describe a novel approach towards coronavirus disease (COVID-19) vaccine design based on engineered human mesenchymal stem cells, with favorable and promising antibody response.

22 Jun 2020

Reassuring news on the Oxford vaccine (AZD1222) against SARS-CoV-2

A new paper from the UK vaccine research group, currently available on the bioRxiv preprint server, reveals that a single dose of ChAdOx1 nCoV-19 (AZD1222) can induce antigen-specific antibody and T cells responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a booster shot additionally enhances antibody production with an increase in neutralizing titers – particularly in pigs.

22 Jun 2020

Synthetic peptide could be an effective COVID-19 treatment and SARS-CoV-2 vaccine

Ligandal, one of the world’s leading genetic medicine companies, has modeled a synthetic peptide that could be an effective COVID-19 treatment and SARS-CoV-2 vaccine.

22 Jun 2020

A highly sensitive and specific antibody test for COVID-19

A new proof-of-concept study by UK researchers, currently available on the medRxiv* preprint server, describes the development of an enzyme-linked immunosorbent assay that can be used when lower levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific-antibodies are present in serum and saliva samples.

21 Jun 2020

Promising candidate monoclonal antibodies show "exquisite potency" against SAR-CoV-2

Researchers at Columbia University, Dana-Farber Cancer Institute, and the National Institutes of Health have identified and characterized a range of monoclonal antibodies that potently neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

21 Jun 2020

Balanced B and T cell response required to control SARS-CoV-2

A new study by researchers in the Netherlands and published on the preprint server bioRxiv in June 2020 describes the differences in T and B cell responses seen in patients with severe COVID-19.

21 Jun 2020

New adjuvant helps induce long-lasting immunity against HIV

Researchers at the Yerkes National Primate Research Center and the Emory Vaccine Center (EVC) are first to show a new adjuvant, 3M-052, helps induce long-lasting immunity against HIV.

20 Jun 2020

COVID-19 plasma therapy safe and improves survival, says large study

Researchers working on COVID-19 therapy with plasma from convalescent patients have found that it is safe and effective and improves the chances of survival among those who are severely ill. The new study titled, “Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients,” is published as a preprint for the journal Mayo Clinic Proceedings.

20 Jun 2020